1.1 Research Scope: Therapies for Most Common Allergic, Infectious Diseases Including COVID-19

1.2 Analysis Framework: Frost & Sullivan Core Value

1.3 Research Methodology: Five Steps Toward Success

1.4 Key Findings of Technology Breakthrough Driving Allergy & Infectious Disease Therapies

2.1 Research Scope: Current Status and Challenges of Allergic and Infectious Diseases

2.2 List of Diseases Discussed in this Research Study

3.1 Most Common Allergic Diseases

3.2 First-line Therapy of Allergic Rhinitis – Antihistamines

3.3 First-line Therapy of Allergic Rhinitis – Other Therapies

3.4 Novel Therapies for Asthma and COPD

3.5 Future Targets and Therapies for Asthma and COPD

3.6 Nonpharmacological Therapy for Atopic Dermatitis

3.7 Pharmacological Treatments of Atopic Dermatitis

3.8 Systemic Therapy for Atopic Dermatitis

3.9 Current and Upcoming Treatments for Sinusitis

3.10 Treatment of Urticaria

3.11 First-line Treatment of Anaphylaxis

3.12 Treatment and Management of Anaphylaxis Through Desensitization

4.1 WHO’s Priority Diseases for R&D in Public Health Emergency

4.2 Treatment of Crimean-Congo Hemorrhagic Fever

4.3 Clinical Trials of Crimean-Congo Hemorrhagic Fever

4.4 First Ebola Virus Vaccine Was Approved by the US FDA in 2019

4.5 Phase 3 and Phase 4 Clinical Trials for Ebola Virus Disease

4.6 Outlook of Treatments for Marburg Virus Infection

4.7 Active Clinical Trials for Marburg Virus Infection

4.8 Upcoming Treatments of Lassa Fever

4.9 Developments in Zika Virus Infection Therapeutics

4.10 Clinical Trials for Interventions of Zika Virus Infections

4.11 Novel System to Reduce the Risk of Transfusion-transmitted Infections

4.12 Prevention and Control of Rift Valley Fever Virus Infection

4.13 Clinical Trials for Rift Valley Fever Virus Infection

4.14 Viruses of the Genus Henipavirus: Nipah & Hendra Virus

4.15 Clinical Trials for Nipah Virus

5. 1 Human Coronaviruses and Their Properties

5.2 BatCoVs and Intermediate Hosts: Reservoirs for Emerging Human CoVs

5.3 Outlook of MERS-CoV Clinical Trials

5.4 Outlook of SARS-CoV and SARS-CoV-2 Clinical Trials

5.5 Repurposed Drugs: Potential Anti-COVID-19 Therapies

5.6 Phase 3 Interventions for SARS-CoV/SARS-CoV2

5.7 Antiviral and Antimalarial Interventions for SARS-CoV/SARS-CoV-2 in Phase 3 Clinical Trials

5.8 Other Phase 3 Interventions for SARS-CoV/SARS-CoV-2

5.9 Phase 4 Clinical Trials for COVID-19

5.10 Currently Used Compounds for Treatment of COVID-19

5.11 Emerging COVID-19 Therapies

5.12 Potential Lentivirus-based Minigene SARS-CoV-2 Vaccines

5.13 Potential Adenovirus and mRNA-based COVID-19 Vaccines

5.14 Clinical Trials of Potential Cell Therapies for COVID-19

5.15 Major Participants in Anti-COVID-19 Drug Discovery

5.16 Innovators Fuelling Anti-COVID-19 Drug Discovery

5.17 Industry Participants Enabling Anti-COVID-19 Drug Discovery

5.18 Novel Biologic Drug for Sialic Acid Dependent Viruses

6.1 Growth Opportunity 1: Personized Therapies for Allergic Diseases

6.2 Growth Opportunity 2: Potential Novel Therapeutics for COVID-19

7.1 Industry Interactions

Legal Disclaimer